<!DOCTYPE html>
<html lang="en-US">
<head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width initial-scale=1.0" />
    <title>VASCEPA (icosapent ethyl) - EPA purity</title>
    <meta name="description" content="Compare VASCEPA, which is ≥96% pure EPA, with omega-3 dietary supplements.">
    <meta name="keywords" content="EPA, DHA, omega-6, fish oil supplements, VASCEPA">
    <link rel="stylesheet" type="text/css" href="../includes/style.css">
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.3/jquery.min.js"></script>
    <script src="../includes/main.js"></script>
    <script type="text/javascript">
        if(navigator.userAgent.match(/iPad/i)) {
            viewport = document.querySelector("meta[name=viewport]");
            viewport.setAttribute('content', 'width=960');
        }
    </script>
    <script src="//use.typekit.net/kfd3zyz.js"></script>
    <script>try{Typekit.load({ async: true });}catch(e){}</script>    <script>try{Typekit.load();}catch(e){}</script>
    <script>
        (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
        (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
        m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
        })(window,document,'script','//www.google-analytics.com/analytics.js','ga');
        ga('create', 'UA-60954107-1', 'auto');
        ga('send', 'pageview');
        
    </script>
    <script src="http://crypto-js.googlecode.com/svn/tags/3.1.2/build/rollups/sha1.js"></script>
    <script src="http://services.revhealthbackend.com/js/urlPassword.js"></script>
</head>

<body>
    <div id="wrapper">
        <div id="currentpg" data-current="managing"></div>
        <div id="top-child-content"></div>
        <div id="content" class="content-wrap">
            <div id="page-content">
                <div class="breadcrumbs">
                    <ul>
                        <a href="impact-of-ldl-c.html">
                            <li><p>Impact of LDL-C</p></li>
                        </a>
                        <a href="epa-and-dha.html">
                            <li><p>EPA and DHA</p></li>
                        </a>
                        <a href="moa-of-epa.html">
                            <li><p>MOA of EPA</p></li>
                        </a>
                        <a href="#">
                            <li class="current-page"><p>EPA purity</p></li>
                        </a>
                        <a href="dietary-supplements.html">
                            <li><p>Dietary supplements</p></li>
                        </a>
                    </ul>
                </div>
                <div class="center-col">
                    <div class="page-text">
                        <h1>Supplements Contain EPA, DHA, Omega‑6, and Other Ingredients That Are Unknown</h1>
                        <p>In the pivotal MARINE trial, VASCEPA 4 g/d increased plasma EPA levels 5-fold from baseline to end of study—at baseline, mean EPA plasma levels were 61.2&nbsp;&micro;g/mL; at the end of 12 weeks of treatment, mean EPA plasma levels were 326.7&nbsp;&micro;g/mL.<sup>1</sup></p>
                        <img class="alignleft" title="EPA in VASCEPA vs dietary supplements" src="../includes/uploads/ANAN1505_Pills2.png" alt="EPA in VASCEPA vs dietary supplements" height="310" width="262">
                        <p>&nbsp;</p>
                        <ul>
                            <li>The increase in LDL-C caused by DHA in some patients may be avoided by using EPA-only VASCEPA. There may be other ingredients within fish oil supplements that are considered nonbeneficial or potentially harmful</li>
                            <li>DHA has been correlated with increases in LDL-C, while omega-6 may have proinflammatory properties<sup>3</sup></li>
                            <li>VASCEPA is obtained naturally from wild, deepwater Pacific Ocean fish predominantly harvested off the South American coast from the families of Engraulidae (anchovies), Carangidae (jacks, pompanos, scads), Clupeidae (sardines, menhadens, herrings), Osmeridae (smelts), Scombridae (mackerels, tunas), and Ammodytidae (sand lances)<sup>4</sup></li>
                        </ul>
                        <p><a class="arrow-link" title="EPA and DHA" href="epa-and-dha.html">Learn more about EPA/DHA</a></p>
                        <div class="clear">
                            <p>DHA, docosahexaenoic acid; LDL-C, low-density lipoprotein cholesterol; EPA, eicosapentaenoic acid; MARINE, Multi-center plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension.</p>
                        </div>
                        <p><a class="button" href="#lightbox-content">Chromatogram</a></p>
                    </div>
                    <div class="load-child-disclaimer"></div>
                    <div class="references">
                        <strong>References: 1.</strong> Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. <em>Postgrad Med.</em> 2014;126(7):7-18. <strong>2.</strong> Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). <em>AM J Cardiol.</em>  2011;108(5):682-690. <strong>3.</strong> Bays H. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians. <em>Drugs Today (Barc).</em> 2008;44(3):205-246. <strong>4.</strong> Data on file. Amarin Pharma Inc., 2012.
                    </div>
                    <div id="lightbox-content">
                        <div id="lightbox-wrapper">
                            <div class="lightbox-div wider-box">
                                <div id="close"><img src="../includes/theme-images/close.png" alt="close"></div>
                                <div class="lightbox-text">
                                    <h1>Vascepa Compared With An Omega-3 Supplement</h1>
                                    <div class="half-title">
                                        <strong>Chromatogram showing the purity of VASCEPA (icosapent ethyl)<sup>3</sup></strong>
                                    </div>
                                    <div class="half-title">
                                        <div><strong>Chromatogram showing the mixed composition of a fish oil supplement<sup>3</sup></strong></div>
                                    </div>
                                    <p><img class="alignnone" title="EPA Chromatogram" src="../includes/uploads/EPA-Chromatogram.png" alt="EPA Chromatogram" width="735" height="328"></p>
                                    <p><strong>Important Safety Information for VASCEPA</strong><br>
                                    The most common reported adverse reaction (incidence &gt;2% and greater than placebo) was arthralgia (2.3% VASCEPA, 1.0% placebo).</p>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="page-sidebar">
                    <div class="load-child-callout"></div>
                    <div class="load-child-disclaimer"></div>
                </div>
            </div>
        </div>
        <div id="child-footer"></div>
    </div>
</body>
</html>